Skip to main content
Gut logoLink to Gut
letter
. 1995 Apr;36(4):639–640. doi: 10.1136/gut.36.4.639

An alternative view of 5-ASA formulations.

J Rhodes, G A Coles
PMCID: PMC1382512  PMID: 7737577

Full text

PDF

Page 639

639

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Vos M., Verdievel H., Schoonjans R., Praet M., Bogaert M., Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut. 1992 Oct;33(10):1338–1342. doi: 10.1136/gut.33.10.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Rijk M. C., van Schaik A., van Tongeren J. H. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol. 1992 Oct;27(10):863–868. doi: 10.3109/00365529209000155. [DOI] [PubMed] [Google Scholar]
  3. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  4. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES